Elevance Slides 9% as Membership Losses Overshadow a Guidance Boost
Elevance Health (ELV) delivered a second quarter that, on paper, looked encouraging — the insurer topped earnings estimates and even raised its full-year outlook. Yet investors focused on the weak spots instead, and they sent the stock down roughly 8.8% on Wednesday. That slide trimmed Elevance’s year-to-date gain to about 10.9%.
In other words, the headline beat simply could not outrun a more troubling trend beneath it.
Where the Membership Cracks Appeared
At the center of the sell-off sat one number: total medical membership. It landed at 44.9 million for the June quarter, slipping about 1% from the prior quarter and 1.5% year over year. A planned transition of a commercial fee-based customer explained part of the decline, while attrition across the company’s individual Affordable Care Act and Medicaid rolls accounted for the rest.
Drilling into the commercial risk-based business sharpens the picture. Individual membership fell 2.3% from a year earlier, and employer group membership dropped a steeper 5.5%. Consequently, even solid pricing could not fully offset the shrinking base.
Rising Costs Add Pressure
Cost trends compounded the worry. The company’s benefit-expense ratio — the share of premiums spent on medical care — climbed 80 basis points to 89.7%, driven largely by higher medical costs in its government business. As a result, margins tightened even as revenue held up.
Management, for its part, struck a measured tone. “The Medicaid environment continues to be dynamic, and we’re managing it with discipline,” Chief Executive Gail Boudreaux told analysts, emphasizing faster detection of cost pressures.
The Numbers Still Beat
Despite the membership erosion, the actual results cleared the bar. Adjusted earnings came in at $7.45 per share — down about 16% year over year, yet comfortably ahead of the $6.21 analysts expected. Operating revenue, meanwhile, edged up to $49.83 billion from $49.42 billion, defying forecasts that called for a decline. Higher premium yields and product revenue powered that top-line surprise.
Looking further down the business, product revenue rose 3.7% and service fees jumped 8.3%, while the Carelon division grew 6%.
Guidance Moves Higher
On the strength of those trends, Elevance nudged its full-year target upward. The company now expects adjusted earnings of at least $27 per share for 2026, up from prior guidance of $26.75 and slightly above the $26.87 consensus. CFO Mark Kaye called the revised outlook “prudent” and grounded in current operating trends.
The Bottom Line
Ultimately, Wednesday’s reaction says less about the quarter Elevance just reported and more about the one investors fear is coming. Boudreaux insisted the company remains confident in returning to “at least 12%” adjusted EPS growth in 2027, but until membership stabilizes and government-cost pressures ease, the market appears unwilling to give management the benefit of the doubt.
